Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02626299 · ClinicalTrials.gov registry record · Phase 3
Assessment of DHA On Reducing Early Preterm Birth
A Phase 3 study, sponsored by University of Kansas Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,100
- Enrollment target
NCT02626299: Completed Phase 3 study, sponsored by University of Kansas Medical Center.
NCT02626299 is a Phase 3 study that has completed, run by University of Kansas Medical Center. The registered enrollment target is 1,100 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (42% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02626299, a Phase 3 study, has completed, sponsored by University of Kansas Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,100 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if giving a larger amount of DHA than currently included in some prenatal supplements can reduce early preterm birth (birth before 34 weeks of pregnancy).
Primary Outcome
Bayesian posterior mean and 95% credible interval of pregnancies which result in an early preterm birth (birth before 34 weeks of pregnancy) by DHA dose
Interventions
- OTHER Placebo
- DRUG Docosahexaenoic acid - 800mg/day
- DRUG Docosahexaenoic acid - 200mg/day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,100 participants |
| Start Date | 2016-06-08 |
| Est. Completion | 2020-10-05 |
| Phase | Phase 3 |
What the finished NCT02626299 record still lists
NCT02626299 is an interventional study that assigns participants to a tested intervention. Its 1,100 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (42% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02626299 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02626299 about?
NCT02626299 is a clinical study titled "Assessment of DHA On Reducing Early Preterm Birth". The purpose of this study is to determine if giving a larger amount of DHA than currently included in some prenatal supplements can reduce early preterm birth (birth before 34 weeks of pregnancy).
What is the current status of trial NCT02626299?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,100 participants. The study started on 2016-06-08. Estimated completion is 2020-10-05.
What interventions are being tested in trial NCT02626299?
The interventions under investigation include: Placebo (OTHER), Docosahexaenoic acid - 800mg/day (DRUG), Docosahexaenoic acid - 200mg/day (DRUG).
Who is sponsoring clinical trial NCT02626299?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02626299's enrollment target sits among peer trials
1,100 252nd of 2000 higher than 1,736 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00710112 · 1,100 participants
Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants
- NCT02688517 · 1,100 participants
Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer
- NCT04743765 · 1,100 participants · NA
HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial
- NCT05638581 · 1,100 participants · Phase 3
Trauma Resuscitation With Low-Titer Group O Whole Blood or Products
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI